27,294 Shares in Smith & Nephew SNATS, Inc. $SNN Bought by Man Group plc

Man Group plc bought a new stake in shares of Smith & Nephew SNATS, Inc. (NYSE:SNN) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 27,294 shares of the medical equipment provider’s stock, valued at approximately $1,712,000.

Several other hedge funds have also bought and sold shares of SNN. Mitsubishi UFJ Asset Management Co. Ltd. bought a new position in shares of Smith & Nephew SNATS during the 2nd quarter valued at approximately $13,812,000. Grandfield & Dodd LLC bought a new stake in Smith & Nephew SNATS during the 2nd quarter worth approximately $13,192,000. Teachers Retirement System of The State of Kentucky lifted its holdings in Smith & Nephew SNATS by 51.0% during the first quarter. Teachers Retirement System of The State of Kentucky now owns 905,100 shares of the medical equipment provider’s stock valued at $28,764,000 after purchasing an additional 305,600 shares in the last quarter. BlackRock Inc. bought a new position in shares of Smith & Nephew SNATS in the second quarter worth approximately $505,323,000. Finally, Deutsche Bank AG purchased a new stake in shares of Smith & Nephew SNATS in the second quarter worth $33,563,000. Institutional investors own 25.64% of the company’s stock.

Analysts Set New Price Targets

Several analysts have recently commented on SNN shares. Morgan Stanley restated an “overweight” rating on shares of Smith & Nephew SNATS in a research report on Wednesday, August 5th. Wall Street Zen raised shares of Smith & Nephew SNATS from a “hold” rating to a “buy” rating in a report on Monday, August 24th. Weiss Ratings cut Smith & Nephew SNATS from a “hold (c+)” rating to a “hold (c)” rating in a report on Thursday, June 11th. Kepler Capital Markets downgraded Smith & Nephew SNATS from a “buy” rating to a “hold” rating in a research report on Thursday, June 4th. Finally, Sanford C. Bernstein set a $31.85 price objective on Smith & Nephew SNATS in a research note on Monday, May 11th. Two investment analysts have rated the stock with a Buy rating, seven have given a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $30.93.

Smith & Nephew SNATS Price Performance

Smith & Nephew SNATS stock opened at $28.98 on Wednesday. The company’s 50-day moving average price is $30.20 and its 200-day moving average price is $31.57. Smith & Nephew SNATS, Inc. has a twelve month low of $28.56 and a twelve month high of $38.79. The company has a debt-to-equity ratio of 0.62, a quick ratio of 1.11 and a current ratio of 2.14.

Smith & Nephew SNATS Announces Dividend

The business also recently disclosed a dividend, which will be paid on Friday, November 6th. Stockholders of record on Friday, October 2nd will be paid a $0.312 dividend. This represents a dividend yield of 205.0%. The ex-dividend date of this dividend is Friday, October 2nd.

About Smith & Nephew SNATS

Smith & Nephew plc is a global medical technology company specializing in the design, development and manufacture of advanced surgical devices, orthopaedic reconstruction implants, trauma and extremities products, sports medicine solutions and wound care therapies. Founded in 1856 in Hull, United Kingdom, the company has grown through both organic innovation and strategic acquisitions to offer a broad portfolio that addresses patient needs across joint replacement, minimally invasive surgery and wound healing.

In its orthopaedics business, Smith & Nephew provides hip and knee replacement systems, modular joint revision implants and biologic solutions for bone repair.